The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).
Mallory Telese, PharmD, BA, BCACP, CSP
Advertisement
Articles by Mallory Telese, PharmD, BA, BCACP, CSP
Advertisement
Latest Updated Articles
Oral Semaglutide Approved to Reduce the Risk of Cardiovascular EventsPublished: January 17th 2026 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5